Merus' (MRUS) "Outperform" Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Merus (NASDAQ:MRUS - Free Report) in a research note released on Monday morning,RTT News reports.

MRUS has been the subject of several other research reports. Piper Sandler assumed coverage on Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 target price on shares of Merus in a research report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and set a $83.00 price target on shares of Merus in a report on Wednesday, April 9th. Guggenheim reaffirmed a "buy" rating and issued a $109.00 price objective on shares of Merus in a report on Friday, March 28th. Finally, Bank of America reduced their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Merus presently has a consensus rating of "Buy" and a consensus target price of $85.31.

Merus Stock Up 0.3 %

Shares of Merus stock traded up $0.15 on Monday, hitting $45.66. 42,835 shares of the company's stock traded hands, compared to its average volume of 707,870. The stock has a market cap of $3.15 billion, a P/E ratio of -11.57 and a beta of 1.02. The firm's 50-day moving average is $44.03 and its 200 day moving average is $44.62. Merus has a 52-week low of $33.19 and a 52-week high of $61.61.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. The business had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Equities research analysts forecast that Merus will post -3.85 EPS for the current year.

Institutional Trading of Merus

Large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its position in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 300 shares in the last quarter. GF Fund Management CO. LTD. increased its position in Merus by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock worth $74,000 after buying an additional 315 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Merus by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock valued at $1,921,000 after acquiring an additional 331 shares during the last quarter. Deutsche Bank AG raised its position in shares of Merus by 0.4% in the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock valued at $4,754,000 after purchasing an additional 416 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Merus by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company's stock worth $2,213,000 after acquiring an additional 540 shares during the period. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.